©2002 Arizona CERT
    
 
Dr. Raymond L. Woosley, MD, PhD
 

Dr. Woosley earned a Ph.D. in Pharmacology from the University of Louisville (1967) and an M.D. degree from the University of Miami (1971). Dr. Woosley completed Post-doctoral training at the University of Louisville in Pharmacology and at Vanderbilt University in Clinical Pharmacology.

Following graduate school, he served as the first scientist employed by Meyer Laboratories (now GSK, Inc.). After returning to study medicine, he graduated from the University of Miami School of Medicine and then specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University. He remained on the faculty and rose to the rank of Professor of Medicine and Pharmacology.

From 1988 to 2001, he was Chairman of the Department of Pharmacology at Georgetown University. In 2001 he assumed the position of Associate Dean for Clinical Research. From 2001 to 2005 he was Vice President for Health Sciences at the University of Arizona and is now President and CEO of The Critical Path Institute.

He has served on many national advisory committees for the NIH, Veterans Administration, the US Pharmacopeial Convention, the Cardiorenal Advisory Committee of the Food and Drug Administration, the Institute of Medicine (National Academy of Sciences) and chairman of the Joint Advisory Committee on Cardiovascular Drugs for the American Heart Association and the American College of Cardiology. He has served as ad hoc consultant for numerous FDA advisory committees, a Special Consultant for the FDA, and a member of the Director's Advisory Committee on Clinical Research for the NIH's National Center for Research Resources.

Dr. Woosley's research has investigated the basic and clinical pharmacology of antiarrhythmic drugs and he is considered an international authority on the drug treatment of arrhythmias. He has demonstrated the importance of active drug metabolites, stereoisomerism and pharmacogenetic differences in drug metabolism as factors influencing the pharmacologic and clinical response to antiarrhythmic drugs, beta adrenergic antagonists, antimalarials and antihistamines such as terfenadine. His research has identified the mechanisms responsible for the greater risk of drug-induced arrhythmias in women. His research has been reported in over 300 publications including 170 original articles, 50 book chapters and 60 invited reviews.

In March of 1990, he received the Rawls-Palmer Award for his contributions to medicine by the American Society of Clinical Pharmacology and Therapeutics. In 2001, he received the Henry Gold Award from the Society. He was selected by practicing physicians to be listed in The Best Doctors in America from 1994-2000.

Return to Faculty Profiles

     
     

The University of Arizona Center for Education and Research on Therapeutics
Arizona Health Sciences Center
Tucson, Arizona 85724-5018

Funded in part by Agency for Healthcare Research and Quality grant 1 U18 HS10385-01

Disclaimer and Waiver
The information presented is intended solely for the purpose of providing general information about health related matters. It is not intended for any other purpose, including, but not limited to, medical or pharmaceutical advice and/or treatment, nor is it intended to substitute for the users' relationships with their own health care/pharmaceutical providers. To that extent, by continued use of this program, the user affirms the understanding of the purpose and releases the University of Arizona, State of Arizona and Arizona Board of Regents from any claims arising out of his/her use of the website.